Dronedarone in Pacemakers Patients With Paroxysmal Atrial Fibrillation (DROPPAF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01070667|
Recruitment Status : Unknown
Verified February 2010 by Eastbourne General Hospital.
Recruitment status was: Not yet recruiting
First Posted : February 18, 2010
Last Update Posted : February 22, 2010
|Condition or disease||Intervention/treatment||Phase|
|Paroxysmal Atrial Fibrillation||Drug: Dronedarone Drug: Placebo||Phase 4|
The study is planned to commence in March 2010 after obtaining Ethics Committee approval. Patients will be randomised to a three month course of dronedarone or placebo. 1:1 double blinded randomisation will be undertaken. At three months, after a one week washout period, the patients will cross-over treatment groups. To achieve a power of 0.8 with a type one error rate 5% detecting a relative difference of 10% primary outcomes the study will require 42 patients. 50 patients in total will be enrolled in the study. The study will take place at Eastbourne District General Hospital. The study duration per patient is 7 months. The overall study duration will be 1 year.
STUDY OVERVIEW Appropriate patients with DDDRP pacemakers with an AF burden of 1-50% detected on pacemaker holters will be identified from the pacing clinic list and the Cardiology Outpatient Department at the Eastbourne District General Hospital. They will be invited to take part after a verbal explanation of the study has been given. If agreement is obtained each patient will be given the Patient Information Sheet and allowed time to consider their participation in the study and to ask relevant questions. If they are still in agreement they will be asked to sign the Patient Consent Form.
Initially, all patients will have all baseline parameters assessed. All patients will stop taking their anti-arrhythmic drugs for a period of one week. Patients will then have a three month course of either dronedarone or placebo according to randomisation in a double blinded fashion. Randomisation will be performed by use of random number tables. At three months data will be collected from patient questionnaires and pacemaker Holter.
There will be a one week washout period at this time. Patients will then cross-over to dronedarone or placebo for a three month period. Data from patient questionnaires and pacemaker Holters will be collected at three months after cross-over.
Patients will then undergo a further week washout period before re-initiating their original anti-arrhythmic therapy.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Dronedarone in Pacemaker Patients With Paroxysmal Atrial Fibrillation|
|Study Start Date :||March 2010|
|Estimated Primary Completion Date :||March 2010|
|Estimated Study Completion Date :||March 2010|
Patients will receive 400 mg of dronedarone per day for 3 months.
400mg orally once per day for 3 months
Other Name: Multaq
Placebo Comparator: Placebo
Patients will receive a placebo tablet once per day for 3 months. AF burden and other parameters described will be monitored from the participants permanent pacemaker. Participants will also be asked to fill out symptom diaries and questionaires.
1 tablet once per day for 3 months. The tablet will appear identical to the active dronedarone tablet.
- To accurately assess, by the use of long term beat to beat pacemaker Holter monitoring, the effect of of dronedarone upon AF burden. [ Time Frame: 3 months ]
- To accurately assess the number of AF episodes, AF frequency and average duration of sinus rhythm. [ Time Frame: 3 months ]
- To assess differences in patient experience of dronedarone and placebo therapies by means of questionnaires. [ Time Frame: 3 months ]
- Quality of life measures - SF-36, visual analogue scores, symptom assessment scores. [ Time Frame: 3 months ]
- Comparison of side effects and major adverse cardiac events. [ Time Frame: 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01070667
|Contact: Steven J Podd, MA, MBBS||01323417400 ext firstname.lastname@example.org|
|Contact: A N Sulke, MD||01323417400 ext email@example.com|
|Eastbourne DGH||Not yet recruiting|
|Eastbourne, East Sussex, United Kingdom, BN21 2UD|
|Contact: Steven J Podd, MA, MBBS 01323417400 ext 4132 firstname.lastname@example.org|
|Contact: A N Sulke, MD 01323417400 ext 5869 email@example.com|
|Principal Investigator:||A N Sulke, MD||East Sussex NHS Trust|